Olmesartan medoxomil: A clinical review

Indian Heart Journal

Volumn 58, Issue 3, 2006, Pages 285-289

  Manoria, P C ^a,d   Manoria, Pankaj ^b   Manoria, Piyush ^c  

^a GANDHI MEDICAL COLLEGE   (India)

^b The Heart Care Clinic   (India)

^c Dept of Forensic Medicine and Toxicology   (India)

^d E/5103 ^*  (India)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Hypertension

Indexed keywords

AMLODIPINE; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; NITRENDIPINE; OLMESARTAN; PLACEBO; VALSARTAN;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 33750587903     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Dahlof B, Devereux R, de Faire U, et al. The losartan intervention for endpoint reduction in hypertension (LIFE) study. Lancet 2002;359:995-1003.
2. Whittaker A. A review of olmesartan medoxomil - a new angiotensin II receptor blocker. Br J Cardiol 2005;12:125-29.
3. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel JM. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91.
4. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical consideration of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999;39:547-59.
5. Neutel JM. Clinical studies of CS-866, a new angiotensin II receptor antagonist. Am J Cardiol 2001;87(Suppl):37C-43C.
6. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker,in healthy subjects. J Clin Pharmacol 2001;41:515-27.
7. Israili ZH, Hall WD. Cough and angioneurotic oedema associated with angiotensin converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
8. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001;19(Suppl 1):S15-S20.
9. Koike H, et al. Olmesartan medoxomil, a novel potent angiotensin blocker. Annu Rep Sankyo Res Lab 2003;55:1-91.
10. Norwood D, Branch E, Smith B, Honeywell M. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast 2002;27:611-18.
11. Van Mieghem W. A multi-centre, double bind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension. J Hypertens 2001;19(Suppl 2):S152.
12. Chrysant SG, Marbury TC, Robinson TD. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425-32.
13. Mallion JM. Data presented at the 15th Eruopean meeting on hypertension during the sympoisa on "The Evolution of Angiotensin Receptor Blockade: More patients, better control, vascular beenfits" at Milan (Italy) June 17, 2005.
14. Williams PA. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension. J Hypertens 2001;19(Suppl 2):300.
15. Ball K. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist Olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension. J Hypertens 2001;19(Suppl 2):153.
16. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003;23:419-30.
17. Fliser D, Bahlmann, K de Groot, Mueller O, Hertel B, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-1107.